Sequenta  
LymphoSIGHT（淋巴细胞免疫球蛋白和T细胞受体测序）平台由Sequenta设计，是对免疫细胞计数的一个平台。用于ALL、慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤。
LymphoSIGHT是一个新型的流式细胞仪，但灵敏度和特异性提高。与流式细胞仪不同的是，LymphoSIGHT可以测定免疫细胞的DNA含量，DNA含量具有很强的适应性，使细胞根据需求产生抗体。“这是遗传多样性的引擎，有万亿种不同组合。这些免疫细胞会产生独特的DNA标签，因此可以确定样本中免疫细胞的特点，” Sequenta执行总裁Tom Willis博士说。

Sequenta is a venture-backed company dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases.